Solvay Healthcare is the UK subsidiary of a major international pharmaceutical company and part of the multi-national Solvay Group, a highly successful chemicals, plastics and pharmaceuticals organisation with expanding worldwide interests. Visit ww.solvay.com for more informaiton.

World-class Products

Solvay Healthcare markets a wide range of products, most of which are the result of Solvay's own pioneering research and development programmes.

Cardiovascular

Cardiovascular disease is the leading cause of death in the UK. Many advances have been made in the past decades, but death rates still remain high. Solvay Healthcare has an innovative range of products to treat cardiovascular disease and has many more in development for the future. Solvay Healthcare focus their current efforts on the treatment of hypertension (raised blood pressure) and savings lives after a heart attack. Solvay Healthcare has a portfolio of 3 cardiology drugs, Teveten and Physiotens (for raised blood pressure) and Omacor® (a life saving treatment for heart attack sufferers).

For further information and the latest updates on Omacor visit www.omacor.co.uk .

Gastroenterology

Solvay Healthcare Ltd has been heavily involved in the gastroenterology therapy area since the launch of lactulose for the treatment of constipation, in the 1960s. This was followed in 1978 by the launch of Colofac for the treatment of irritable bowel syndrome, and in 1985, by the launch of Creon® for patients with cystic fibrosis. In more recent times, Solvay has expanded its gastroenterology portfolio by successfully bringing line extensions of these popular products to the market, including Creon 40000 in 2002. The company continues to focus on gastroenterology, and further product launches are anticipated in the near future.

For further information and the latest updates on cystic fibrosis and Creon visit www.creoninfo.co.uk .

For a useful, non-promotional source of information for patients with Irritable Bowel Syndrome (IBS) please visit www.ibsinfo.co.uk . This site also includes a section designed specifically for healthcare professionals.

Influenza

Influvac® influenza vaccine  is a sub-unit vaccine, which means that it contains only those parts of the influenza virus that are absolutely needed for effective vaccination. The sub-unit Influenza vaccine Influvac® has been on the market since the early eighties.

For further information, customer service information and account management details (UK customers only) please visit www.influvac.co.uk .

Neuroscience

Parkinson's Disease is the most common neurodegenerative disease after Alzheimer's disease.  There are estimated to be at least 120,000 sufferers in the United Kingdom alone.  Including their friends and relatives, this means approximately 1 million people are directly or indirectly affected by Parkinson's.

Parkinson's Disease is not just a disorder affecting patients' movement - it is a very complex condition affecting every part of a person's daily life.

In January 2005, Solvay Pharmaceuticals acquired Neopharma AB, a company based in Uppsala, Sweden and added Duodopa®, an important new therapy for people suffering from advanced Parkinson's Disease, to its product portfolio which will be available in the second quarter of 2006. 

Duodopa® is a treatment based on continuous dopaminergic stimulation by means of a formulation of well-known tried and tested substances, levodopa and carbidopa, dispersed as a viscous gel.  Using a specially designed patient-operated portable pump, the drug is continuously delivered via a tube directly into the duodenum. 

For further information and the latest updates on Duodopa visit www.duodopa.co.uk . This site also includes a section designed specifically for healthcare professionals.

Hormone Replacement Therapy (HRT)

Solvay Healthcare has extensive experience in Hormone Replacement Therapy (HRT), for the treatment of menopausal symptoms and second line prevention of osteoporosis.

Solvay Healthcare's HRT products include:

• Femoston - for women who are still experiencing a natural monthly bleed.
• Femoston-conti - for women, 54+, who no longer experience monthly bleeds.

Many other products are long-established market leaders in their fields in the UK and/or worldwide such as Serc® for treating certain disorders of balance and Faverin® for management of mood disorders.

Several new products in cardiology and gastroenterology are in development, giving us a healthy product line for future growth and expansion. For the latest news on our product pipeline and recent partnerships and acquisitions affecting the UK market see our news section . For a more international view of our activities please visit www.solvay.com .